Research & development
Commited to developing cancer therapeutics designed to inhibit cancer stern cell pathways.
Cancer is the number one cause of death in the developed world, expected to increase in the next decades. For advanced cancer, survival rates have remained steady for the last 30 years.
There is a need for novel approaches to cancer therapy that can make a quantum leap in patient care. While recent approaches to immunotherapy have made significant advances, many patients still experience relapse and metastasis. Metastasis and relapses are the primary cause of deaths due to cancer. Resilient cancer stem cells are more resistant to conventional cancer therapy (Chemotherapy and radiotherapy) so they persist after treatment and can seed new tumors. At StemTek we believe that the cancer stem cell compartment of the tumor must be targeted to get a durable response in cancer treatment.
Drug screening against cancer stem cells based on 3D cell culture systems allow for stronger, more efficient and reliable drug screening than conventional 2D based monolayer culture systems currently used by pharmaceutical industry. StemTek works on research that allows biotech and pharmaceutical companies to profile their pipeline of compounds to measure their effect on cancer stem cell populations.
Research & development program
The queen bee of the tumor
StemTek R&D is supported by collaborations and alliances with leadi...
Putting an end to relapse